BR1100580A - Composto e complexo - Google Patents
Composto e complexoInfo
- Publication number
- BR1100580A BR1100580A BR1100580-7A BR1100580A BR1100580A BR 1100580 A BR1100580 A BR 1100580A BR 1100580 A BR1100580 A BR 1100580A BR 1100580 A BR1100580 A BR 1100580A
- Authority
- BR
- Brazil
- Prior art keywords
- complex
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21149688A | 1988-06-24 | 1988-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR1100580A true BR1100580A (pt) | 2000-06-06 |
Family
ID=22787153
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR1100580-7A BR1100580A (pt) | 1988-06-24 | 1997-05-13 | Composto e complexo |
| BR1100574-2A BR1100574A (pt) | 1988-06-24 | 1997-05-13 | Ligantes macrocìclicos e complexos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR1100574-2A BR1100574A (pt) | 1988-06-24 | 1997-05-13 | Ligantes macrocìclicos e complexos |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US5652361A (pt) |
| CN (2) | CN1033030C (pt) |
| AU (1) | AU3705889A (pt) |
| BR (2) | BR1100580A (pt) |
| PT (1) | PT90959B (pt) |
| ZA (1) | ZA894792B (pt) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU623901B2 (en) * | 1988-01-26 | 1992-05-28 | Nycomed As | Paramagnetic compounds comprising chelating moiety, linker group macro molecule and paramagnetic metal |
| JP2831073B2 (ja) * | 1988-06-24 | 1998-12-02 | ザ ダウ ケミカル カンパニー | 大環状二官能キレート剤、その錯体及びそれらの抗体接合体 |
| US6139603A (en) * | 1989-02-22 | 2000-10-31 | L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude | Process for recovering oxygen |
| US7597886B2 (en) * | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US7820798B2 (en) * | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
| DE19652387A1 (de) * | 1996-12-04 | 1998-06-10 | Schering Ag | Macrocyclische Metallkomplexcarbonsäuren, ihre Verwendung sowie Verfahren zu ihrer Herstellung |
| US6231832B1 (en) | 1998-03-23 | 2001-05-15 | Brookhaven Science Associates | Radiopharmaceutical stannic Sn-117m chelate compositions and methods of use |
| EP2357192A1 (en) | 1999-02-26 | 2011-08-17 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
| EP1274720A4 (en) | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | FUSION PROTEINS CONTAINING ALBUMIN |
| US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| WO2001096528A2 (en) | 2000-06-15 | 2001-12-20 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| AU2001285066B2 (en) | 2000-08-18 | 2006-06-29 | Human Genome Sciences, Inc. | Binding polypeptides for B lymphocyte stimulator protein (BLYS) |
| US6670456B2 (en) | 2001-02-28 | 2003-12-30 | Dow Global Technologies Inc. | Actinium-225 complexes and conjugates for targeted radiotherapy |
| DE60236646D1 (de) | 2001-04-13 | 2010-07-22 | Human Genome Sciences Inc | Anti-VEGF-2 Antikörper |
| US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| PT1463751E (pt) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Proteínas de fusão de albumina |
| JP2005523688A (ja) * | 2002-01-18 | 2005-08-11 | ブリストル−マイヤーズ スクイブ カンパニー | タンパク質チロシンキナーゼおよび／またはタンパク質チロシンキナーゼ経路と相互作用する化合物の活性を予測するためのポリヌクレオチドおよびポリペプチドの同定 |
| WO2003104428A2 (en) * | 2002-01-21 | 2003-12-18 | Vaccinex, Inc. | Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| WO2003085093A2 (en) * | 2002-04-01 | 2003-10-16 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
| JP2005535572A (ja) | 2002-04-12 | 2005-11-24 | メディミューン，インコーポレーテッド | 組換え抗インターロイキン−９抗体 |
| CA2548180C (en) * | 2003-12-04 | 2014-02-04 | Vaccinex, Inc. | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
| JP5010923B2 (ja) | 2004-02-09 | 2012-08-29 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | アルブミン融合蛋白質 |
| CA2569461A1 (en) | 2004-06-09 | 2005-12-29 | Kereos, Inc. | Lipophilic derivatives of chelate monoamides |
| WO2006020779A2 (en) * | 2004-08-10 | 2006-02-23 | Dow Global Technologies Inc. | Targeting chelants and chelates |
| BRPI0611069A2 (pt) | 2005-05-06 | 2010-11-09 | Zymogenetics Inc | anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma |
| CA2626082C (en) | 2005-10-13 | 2017-04-11 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| CA2646611A1 (en) | 2006-03-21 | 2008-05-22 | Genentech, Inc. | Combinatorial therapy |
| WO2007126730A1 (en) * | 2006-03-29 | 2007-11-08 | Isotherapeautics Group Llc | Radionuclide therapy for urinary bladder cancer |
| AU2007261247A1 (en) * | 2006-06-22 | 2007-12-27 | Vaccinex, Inc. | Anti-C35 antibodies for treating cancer |
| CN103044550A (zh) | 2006-09-01 | 2013-04-17 | 津莫吉尼蒂克斯公司 | Il-31单克隆抗体的可变区序列和使用方法 |
| GB0624587D0 (en) * | 2006-12-08 | 2007-01-17 | Univ Muenchen Tech | Chelating agent |
| MX340566B (es) * | 2007-03-27 | 2016-07-14 | Radiomedix Inc | Composiciones para formacion de imagen objetivo y terapia. |
| KR101603109B1 (ko) | 2007-12-07 | 2016-03-25 | 지모제넥틱스, 인코포레이티드 | Ｉｌ-31에 특이적인 인간화된 항체 분자 |
| JP5690593B2 (ja) | 2007-12-26 | 2015-03-25 | ヴァクシネックス， インコーポレイテッド | 抗ｃ３５抗体併用療法および方法 |
| CN102300866B (zh) * | 2008-12-02 | 2015-08-26 | 墨尔本大学 | 作为放射性药物的含氮大环共轭物 |
| WO2010093993A2 (en) | 2009-02-12 | 2010-08-19 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
| JP6051048B2 (ja) | 2009-03-25 | 2016-12-21 | ジェネンテック， インコーポレイテッド | 新規な抗α５β１抗体及びその使用 |
| US9556272B2 (en) | 2009-11-11 | 2017-01-31 | The Trustees Of The University Of Pennsylvania | Anti-TEM1 antibodies and uses thereof |
| EP2569335B1 (en) | 2010-05-14 | 2018-08-22 | Orega Biotech | Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists |
| PL2721045T3 (pl) | 2011-06-20 | 2017-11-30 | Radiomedix Inc. | Kompozycie, metody syntezy i zastosowanie węglowodanowych środków ukierunkowanych |
| US10717741B2 (en) * | 2011-07-07 | 2020-07-21 | Australian Nuclear Science And Technology Organisation | Cryptate compounds |
| WO2013162748A1 (en) | 2012-04-27 | 2013-10-31 | The Trustees Of The University Of Pennsylvania | Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof |
| TWI689520B (zh) | 2014-05-30 | 2020-04-01 | 漢霖生技股份有限公司 | 抗表皮生長因子受體（ｅｇｆｒ）抗體 |
| JP6655074B2 (ja) | 2014-06-20 | 2020-02-26 | ジェネンテック， インコーポレイテッド | シャガシンに基づく足場組成物、方法及び使用 |
| WO2016161390A1 (en) | 2015-04-03 | 2016-10-06 | Eureka Therapeutics, Inc. | Constructs targeting afp peptide/mhc complexes and uses thereof |
| EP3286227A2 (en) | 2015-04-24 | 2018-02-28 | F. Hoffmann-La Roche AG | Multispecific antigen-binding proteins |
| WO2017180713A1 (en) | 2016-04-13 | 2017-10-19 | Orimabs Ltd. | Anti-psma antibodies and use thereof |
| SMT202500445T1 (it) | 2016-09-16 | 2026-01-12 | Shanghai Henlius Biotech Inc | Anticorpi anti-pd-1 per l'uso nel trattamento del cancro |
| TW201831517A (zh) | 2017-01-12 | 2018-09-01 | 美商優瑞科生物技術公司 | 靶向組織蛋白h3肽/mhc複合體之構築體及其用途 |
| IL270138B2 (en) | 2017-04-26 | 2025-08-01 | Eureka Therapeutics Inc | Structures that specifically recognize glypican 3 and their uses |
| FR3069245B1 (fr) * | 2017-07-21 | 2019-07-26 | Guerbet | Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales |
| CN109384737A (zh) * | 2017-08-04 | 2019-02-26 | 天津科伦药物研究有限公司 | 一种四氮杂环钇络合物及其制备方法和应用 |
| BR112020014591A2 (pt) | 2018-03-14 | 2020-12-01 | Beijing Xuanyi Pharmasciences Co., Ltd. | anticorpos anticlaudina 18.2 |
| CA3103936A1 (en) | 2018-06-18 | 2019-12-26 | Eureka Therapeutics, Inc. | Constructs targeting prostate-specific membrane antigen (psma) and uses thereof |
| CN112300279A (zh) | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
| KR102882392B1 (ko) * | 2019-12-20 | 2025-11-06 | 엔알지 팔라스 비.브이. | 금속의 크로마토그래피 분리 |
| CN110818795B (zh) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | 抗tigit抗体和使用方法 |
| WO2022116877A1 (en) | 2020-12-02 | 2022-06-09 | Shanghai Henlius Biotech, Inc. | ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE |
| JP2025501522A (ja) | 2021-12-17 | 2025-01-22 | シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド | 抗ｏｘ４０抗体及び使用方法 |
| AU2022408865A1 (en) | 2021-12-17 | 2024-07-04 | Shanghai Henlius Biologics Co., Ltd. | Anti-ox40 antibodies, multispecific antibodies and methods of use |
| CN118974096A (zh) | 2022-03-25 | 2024-11-15 | 上海复宏汉霖生物技术股份有限公司 | 抗msln抗体及使用方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4647447A (en) * | 1981-07-24 | 1987-03-03 | Schering Aktiengesellschaft | Diagnostic media |
| US4472509A (en) * | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US4454106A (en) * | 1982-06-07 | 1984-06-12 | Gansow Otto A | Use of metal chelate conjugated monoclonal antibodies |
| SE8301395L (sv) * | 1983-03-15 | 1984-09-16 | Wallac Oy | Kelatiserande foreningar med funktionella grupper vilka tillater kovalent koppling till bio-organiska molekyler |
| US4678667A (en) * | 1985-07-02 | 1987-07-07 | 501 Regents of the University of California | Macrocyclic bifunctional chelating agents |
| EP0232751B1 (en) * | 1986-01-23 | 1991-09-11 | E.R. Squibb & Sons, Inc. | 1-substituted-4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| US4885363A (en) * | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| GB8603537D0 (en) * | 1986-02-13 | 1986-03-19 | Parker D | Conjugate compound |
| DE3625417C2 (de) * | 1986-07-28 | 1998-10-08 | Schering Ag | Tetraazacyclododecan-Derivate |
| US5057302A (en) * | 1987-02-13 | 1991-10-15 | Abbott Laboratories | Bifunctional chelating agents |
| US4994560A (en) * | 1987-06-24 | 1991-02-19 | The Dow Chemical Company | Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies |
| GB8719041D0 (en) * | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
-
1989
- 1989-06-23 CN CN89106401A patent/CN1033030C/zh not_active Expired - Lifetime
- 1989-06-23 PT PT90959A patent/PT90959B/pt not_active IP Right Cessation
- 1989-06-23 ZA ZA894792A patent/ZA894792B/xx unknown
- 1989-06-26 AU AU37058/89A patent/AU3705889A/en not_active Abandoned
-
1993
- 1993-03-08 US US08/028,050 patent/US5652361A/en not_active Expired - Lifetime
-
1994
- 1994-12-15 CN CN94119133A patent/CN1050836C/zh not_active Expired - Lifetime
-
1997
- 1997-05-13 BR BR1100580-7A patent/BR1100580A/pt active Search and Examination
- 1997-05-13 BR BR1100574-2A patent/BR1100574A/pt active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CN1109469A (zh) | 1995-10-04 |
| PT90959A (pt) | 1989-12-29 |
| AU3705889A (en) | 1990-01-04 |
| CN1033030C (zh) | 1996-10-16 |
| CN1044095A (zh) | 1990-07-25 |
| CN1050836C (zh) | 2000-03-29 |
| ZA894792B (en) | 1991-04-24 |
| US5652361A (en) | 1997-07-29 |
| BR1100574A (pt) | 2000-06-06 |
| PT90959B (pt) | 1995-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATA901789A (de) | Somatostatinpeptid | |
| BR8806093A (pt) | Trepano | |
| ATA900689A (de) | Calcitoninpeptide | |
| DK348289A (da) | Forbindelser | |
| DK188690A (da) | Neutrocyt-aktiverende peptid-2 | |
| DK184489D0 (da) | Bicyclodioner | |
| NO176872C (no) | Sentrifugalsikt | |
| FI91488B (fi) | Seula | |
| BR8902098A (pt) | Eletrolisador | |
| DK113291D0 (da) | Homogent enzymimmunassay | |
| DK137889D0 (da) | Foldeaeske | |
| BR8906898A (pt) | Jamela | |
| DK182290A (da) | Foldeaeske | |
| DK165575C (da) | Loeftesele | |
| DE68926367D1 (de) | Hydroxymethylcyclobutylpurine | |
| DD277186A3 (de) | Waelzlagerseparator | |
| IT8812575A0 (it) | Parallelografo e tecnigrafo | |
| BR6801964U (pt) | Fecho | |
| SE8800664D0 (sv) | Sikt | |
| ATA14288A (de) | Zugeinheit | |
| BR8907290A (pt) | Diisopropilbenzeno-bis-peneoalcanoatos | |
| BR6802833U (pt) | Municao subcalibrada - 90mm | |
| BR6800108U (pt) | Supercross | |
| DK137688D0 (da) | Gaffelloeftevogn | |
| SE8800360D0 (sv) | Beleggningskomposition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AN | Processing applications according to articles 230 and 231 of law 9279/96: notification of filing an application | ||
| HHFK | Processing applications according to articles 230 and 231 of law 9.279/96: republication | ||
| MT | Patent procedure suspended until requirement met - articles 230 and 231 of law 9279/96 | ||
| MT | Patent procedure suspended until requirement met - articles 230 and 231 of law 9279/96 | ||
| FGAN | Processing applications according to articles 230 and 231 of law 9.279/96: granting | ||
| NB | Patent issued - articles 230 and 231 of law 9279/96 | ||
| HJEG | Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law |